Preventive effects of pravastatin on thrombin-triggered vascular responses via Akt/eNOS and RhoA/Rac1 pathways in vivo

Cardiovascular Research

Volumn 88, Issue 3, 2010, Pages 492-501

  Ohkawara, Hiroshi ^a   Ishibashi, Toshiyuki ^a,e   Saitoh, Shu Ichi ^a   Inoue, Nobutaka ^b   Sugimoto, Koichi ^a   Kamioka, Masashi ^a   Uekita, Hironori ^a   Kaneshiro, Takashi ^a   Ando, Katsuya ^a   Takuwa, Yoh ^c   Maruyama, Yukio ^d   Takeishi, Yasuchika ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b KOBE ROSAI HOSPITAL   (Japan)

^c KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^d HOSHI GENERAL HOSPITAL   (Japan)

^e National Hospital Organization   (Japan)

Author keywords

Akt; eNOS; Rac1; RhoA; Statin

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; LIPID; PRAVASTATIN; PROTEIN KINASE B; RAC1 PROTEIN; REACTIVE OXYGEN METABOLITE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; THROMBIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; CORONARY ARTERY DILATATION; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME MODIFICATION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; HEART PROTECTION; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; RAT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SPONTANEOUSLY HYPERTENSIVE RAT; WISTAR RAT;

ANIMALS; ANTICHOLESTEREMIC AGENTS; AORTA; CORONARY VESSELS; DISEASE MODELS, ANIMAL; GUANOSINE TRIPHOSPHATE; INJECTIONS, INTRAVENOUS; MALE; NADPH OXIDASE; NITRIC OXIDE SYNTHASE TYPE III; PRAVASTATIN; PROTO-ONCOGENE PROTEINS C-AKT; RAC1 GTP-BINDING PROTEIN; RATS; RATS, INBRED SHR; RATS, WISTAR; REACTIVE OXYGEN SPECIES; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; THROMBIN; VASODILATION;

EID: 78149293218     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvq221     Document Type: Article

References (31)

1. Harrison DG. Cellular and molecular mechanism of endothelial cell dysfunction. J Clin Invest 1997;100:2153-2157.
2. Ross R. Atherosclerosis\-an inflammatory disease. N Engl J Med 1999;340:115-126.
3. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998;273:24266-24271.
4. Sugimoto K, Ishibashi T, Sawamura T, Inoue N, Kamioka M, Uekita H et al. LOX-1-MT1-MMP axis is crucial for RhoA and Rac1 activation induced by oxidized low-density lipoprotein in endothelial cells. Cardiovasc Res 2009;84:127-136.
5. Sanlioglu S, Williams CM, Samavati L, Butler NS, Wang G, McCray PB Jr et al. Lipo-polysaccharide induces Rac1-dependent reactive oxygen species formation and coordinates tumor necrosis factor-alpha secretion through IKK regulation of NF-kappa B. J Biol Chem 2001;276:30186-30198.
6. Wilensky RL, Bourdillon PD, Vix VA, Zeller JA. Intracoronary artery thrombus formation in unstable angina: a clinical, biochemical and angiographic correlation. J Am Coll Cardiol 1993;21:692-699.
7. Patterson C, Ruef J, Madamanchi NR, Barry-Lane P, Hu Z, Horaist C et al. Stimulation of a vascular smooth muscle cell NAD(P)H oxidase by thrombin: evidence that p47(phox) may participate in forming this oxidase in vitro and in vivo. J Biol Chem 1999;274:19814-19822.
8. Brandes RP, Miller FJ, Beer S, Haendeler J, Hoffmann J, Ha T et al. The vascular NADPH oxidase subunit p47phox is involved in redox-mediated gene expression. Free Radic Biol Med 2002;32:1116-1122.
9. Ohkawara H, Ishibashi T, Sakamoto T, Sugimoto K, Nagata K, Yokoyama K et al. Thrombin-induced rapid geranylgeranylation of RhoA as an essential process for RhoA activation in endothelial cells. J Biol Chem 2005;280:10182-10188.
10. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C et al. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278.
11. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T et al. MEGA Study Group Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006;368: 1155-1163.
12. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998;97:1440-1445.
13. Wassmann S, Faul A, Hennen B, Scheller B, Bohm M, Nickenig G. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme: a reductase inhibition on coronary endothelial function. Circ Res 2003;93:e98-e103.
14. Gehr TW, Sica DA, Slugg PH, Hammett JL, Raymond R, Ford NF. The pharmacoki-netics of pravastatin in patients on chronic hemodialysis. Eur J Clin Pharmacol 1997; 53:117-121.
15. Koitabashi Y, Kumai T, Matsumoto N, Watanabe M, Sekine S, Yanagida Y. Orange juice increased the bioavailability of pravastatin, 3-hydroxy-3- methylglutaryl CoA reductase inhibitor, in rats and healthy human subjects. Life Sci 2006;78:2852-2859.
16. Kivistö KT, Grisk O, Hofmann U, Meissner K, Möritz KU, Ritter C et al. Disposition of oral and intravenous pravastatin in MRP2-deficient TR-rats. Drug Metab Dispos 2005; 33:1593-1596.
17. Saitoh S, Zhang C, Tune JD, Potter B, Kiyooka T, Rogers PA et al. Hydrogen peroxide: a feed-forward dilator that couples myocardial metabolism to coronary blood flow. Arterioscler Thromb Vasc Biol 2006;26:2614-2621.
18. 2+ signaling pathways in endothelial cells. J Cell Physiol 2009;220:706-715.
19. Shindo J, Ishibashi T, Yokoyama K, Nakazato K, Ohwada T, Shiomi M et al. Granulocyte-macrophage colony-stimulating factor prevents the progression of atherosclerosis via changes in the cellular and extracellular composition of atherosclerotic lesions in Watanabe heritable hyperlipidemic rabbits. Circulation 1999;99: 2150-2156.
20. Ejiri J, Inoue N, Kobayashi S, Shiraki R, Otsui K, Honjo T et al. Possible role of brain-derived neurotrophic factor in the pathogenesis of coronary artery disease. Circulation 2005;112:2114-2120.
21. Miller FJ Jr, Gutterman DD, Rios CD, Heistad DD, Davidson BL. Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis. Circ Res 1998;82:1298-1305.
22. Yokoyama K, Ishibashi T, Ohkawara H, Kimura J, Matsuoka I, Sakamoto T et al. HMG-CoA reductase inhibitors suppress intracellular calcium mobilization and membrane current induced by lysophosphatidylcholine in endothelial cells. Circulation 2002;105:962-967.
23. Ishibashi T, Sakamoto T, Ohkawara H, Nagata K, Sugimoto K, Sakurada S et al. Integral role of RhoA activation in monocyte adhesion-triggered tissue factor expression in endothelial cells. Arterioscler Thromb Vasc Biol 2003;23:681-687.
24. Shibuki K, Okada D. Endogenous nitric oxide release required for long-term synaptic depression in the cerebellum. Nature 1991;349:326-328.
25. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angio-genesis in normocholesterolemic animals. Nat Med 2000;6:1004-1010.
26. Harris MB, Blackstone MA, Sood SG, Li C, Goolsby JM, Venema VJ et al. Acute activation and phosphorylation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Am J Physiol Heart Circ Physiol 2004;287:H560-H566.
27. Wassmann S, Laufs U, Muller K, Konkol C, Ahlbory K, Baumer AT et al. Cellular anti-oxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002; 22:300-305.
28. Price MO, Atkinson SJ, Knaus UG, Dinauer MC. Rac activation induces NADPH oxidase activity in transgenic COSphox cells, and the level of superoxide production is exchange factor-dependent. J Biol Chem 2002;277:19220-19228.
29. Mizrahi A, Molshanski-Mor S, Weinbaum C, Zheng Y, Hirshberg M, Pick E. Activation of the phagocyte NADPH oxidase by Rac Guanine nucleotide exchange factors in conjunction with ATP and nucleoside diphosphate kinase. J Biol Chem 2005;280: 3802-3811.
30. Sakamoto T, Kojima S, Ogawa H, Shimomura H, Kimura K, Ogata Y et al. Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese. Am J Cardiol 2006;97:1165-1171.
31. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Am Med Assoc 2000;283:1867-1875.